Last reviewed · How we verify
AP-002
At a glance
| Generic name | AP-002 |
|---|---|
| Also known as | no other names |
| Sponsor | Altum Pharmaceuticals INC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of AP-002 in Patients With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP-002 CI brief — competitive landscape report
- AP-002 updates RSS · CI watch RSS
- Altum Pharmaceuticals INC portfolio CI